BioPharma Dive staff's articles Biotechnology FDA cancels adcomm on Biohaven drug; Catalent lays off staff Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland. Written by BioPharma Dive staff August 23, 2025August 23, 2025 Saving Bookmark this article Bookmarked Biotechnology Ionis gets a milestone approval; Another top FDA official to step down The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals. Written by BioPharma Dive staff December 23, 2024December 23, 2024 Saving Bookmark this article Bookmarked Biotechnology Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. Written by BioPharma Dive staff June 5, 2024June 5, 2024 Saving Bookmark this article Bookmarked
Biotechnology FDA cancels adcomm on Biohaven drug; Catalent lays off staff Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland. Written by BioPharma Dive staff August 23, 2025August 23, 2025 Saving Bookmark this article Bookmarked
Biotechnology Ionis gets a milestone approval; Another top FDA official to step down The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals. Written by BioPharma Dive staff December 23, 2024December 23, 2024 Saving Bookmark this article Bookmarked
Biotechnology Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. Written by BioPharma Dive staff June 5, 2024June 5, 2024 Saving Bookmark this article Bookmarked
